Research ExplorerPublicationsEfficacy of chemotherapy on overall survival in metastatic s...

Efficacy of chemotherapy on overall survival in metastatic sarcomatoid bladder cancer patients

Standard

Efficacy of chemotherapy on overall survival in metastatic sarcomatoid bladder cancer patients. / Tappero, Stefano; Sorce, Gabriele; Panunzio, Andrea; Hohenhorst, Lukas; Garcia, Cristina Cano; Piccinelli, Mattia Luca; Tian, Zhe; Parodi, Stefano; Chun, Felix K H; Graefen, Markus; Antonelli, Alessandro; De Cobelli, Ottavio; Saad, Fred; Shariat, Shahrokh F; Montorsi, Francesco; Suardi, Nazareno R; Borghesi, Marco; Terrone, Carlo; Karakiewicz, Pierre I.

In: CENT EUR J UROL, Vol. 75, No. 4, 2022, p. 352-356.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Tappero, S, Sorce, G, Panunzio, A, Hohenhorst, L, Garcia, CC, Piccinelli, ML, Tian, Z, Parodi, S, Chun, FKH, Graefen, M, Antonelli, A, De Cobelli, O, Saad, F, Shariat, SF, Montorsi, F, Suardi, NR, Borghesi, M, Terrone, C & Karakiewicz, PI 2022, 'Efficacy of chemotherapy on overall survival in metastatic sarcomatoid bladder cancer patients', CENT EUR J UROL, vol. 75, no. 4, pp. 352-356. https://doi.org/10.5173/ceju.2022.142

APA

Tappero, S., Sorce, G., Panunzio, A., Hohenhorst, L., Garcia, C. C., Piccinelli, M. L., Tian, Z., Parodi, S., Chun, F. K. H., Graefen, M., Antonelli, A., De Cobelli, O., Saad, F., Shariat, S. F., Montorsi, F., Suardi, N. R., Borghesi, M., Terrone, C., & Karakiewicz, P. I. (2022). Efficacy of chemotherapy on overall survival in metastatic sarcomatoid bladder cancer patients. CENT EUR J UROL, 75(4), 352-356. https://doi.org/10.5173/ceju.2022.142

Vancouver

Tappero S, Sorce G, Panunzio A, Hohenhorst L, Garcia CC, Piccinelli ML et al. Efficacy of chemotherapy on overall survival in metastatic sarcomatoid bladder cancer patients. CENT EUR J UROL. 2022;75(4):352-356. https://doi.org/10.5173/ceju.2022.142

Bibtex

@article{74113b9e2d0a4ebf80b0f299afa8dc22,
title = "Efficacy of chemotherapy on overall survival in metastatic sarcomatoid bladder cancer patients",
abstract = "INTRODUCTION: The role of chemotherapy in metastatic sarcomatoid bladder cancer (mSBC) is unknown. The current work aimed to test the effect of chemotherapy on overall survival (OS) in mSBC patients.MATERIAL AND METHODS: Using the Surveillance, Epidemiology and End Results database (2001-2018), we identified 110 mSBC patients of all T and N stages (TanyNanyM1). Kaplan-Meier plots and Cox regression models were used. Covariates consisted of type of surgical treatment (no treatment vs radical cystectomy vs other), and patient age. The endpoint of interest was OS.RESULTS: In 110 mSBC patients, 46 (41.8%) were exposed to chemotherapy vs 64 (58.2%) who were chemotherapy naive. Chemotherapy exposed patients were younger (median age 66 vs 70, p = 0.005). Median OS was 8 months in chemotherapy exposed vs 2 months in chemotherapy naive patients. In univariable Cox regression models, chemotherapy exposure was associated with a hazard ratio (HR) of 0.58 (p = 0.007).In multivariable Cox regression models adjusted for case mix, chemotherapy exposure was associated with a HR of 0.60 (p = 0.016).CONCLUSIONS: To the best of our knowledge, this is the first report of chemotherapy effect on OS in mSBC patients. OS is extremely poor. Nonetheless, it is improved in a statistically significant and clinically meaningful fashion, when chemotherapy is administered.",
author = "Stefano Tappero and Gabriele Sorce and Andrea Panunzio and Lukas Hohenhorst and Garcia, {Cristina Cano} and Piccinelli, {Mattia Luca} and Zhe Tian and Stefano Parodi and Chun, {Felix K H} and Markus Graefen and Alessandro Antonelli and {De Cobelli}, Ottavio and Fred Saad and Shariat, {Shahrokh F} and Francesco Montorsi and Suardi, {Nazareno R} and Marco Borghesi and Carlo Terrone and Karakiewicz, {Pierre I}",
note = "Copyright by Polish Urological Association.",
year = "2022",
doi = "10.5173/ceju.2022.142",
language = "English",
volume = "75",
pages = "352--356",
journal = "CENT EUR J UROL",
issn = "2080-4806",
publisher = "Panstwowy Zaklad Wydawnictw Lekarskich",
number = "4",

}

RIS

TY - JOUR

T1 - Efficacy of chemotherapy on overall survival in metastatic sarcomatoid bladder cancer patients

AU - Tappero, Stefano

AU - Sorce, Gabriele

AU - Panunzio, Andrea

AU - Hohenhorst, Lukas

AU - Garcia, Cristina Cano

AU - Piccinelli, Mattia Luca

AU - Tian, Zhe

AU - Parodi, Stefano

AU - Chun, Felix K H

AU - Graefen, Markus

AU - Antonelli, Alessandro

AU - De Cobelli, Ottavio

AU - Saad, Fred

AU - Shariat, Shahrokh F

AU - Montorsi, Francesco

AU - Suardi, Nazareno R

AU - Borghesi, Marco

AU - Terrone, Carlo

AU - Karakiewicz, Pierre I

N1 - Copyright by Polish Urological Association.

PY - 2022

Y1 - 2022

N2 - INTRODUCTION: The role of chemotherapy in metastatic sarcomatoid bladder cancer (mSBC) is unknown. The current work aimed to test the effect of chemotherapy on overall survival (OS) in mSBC patients.MATERIAL AND METHODS: Using the Surveillance, Epidemiology and End Results database (2001-2018), we identified 110 mSBC patients of all T and N stages (TanyNanyM1). Kaplan-Meier plots and Cox regression models were used. Covariates consisted of type of surgical treatment (no treatment vs radical cystectomy vs other), and patient age. The endpoint of interest was OS.RESULTS: In 110 mSBC patients, 46 (41.8%) were exposed to chemotherapy vs 64 (58.2%) who were chemotherapy naive. Chemotherapy exposed patients were younger (median age 66 vs 70, p = 0.005). Median OS was 8 months in chemotherapy exposed vs 2 months in chemotherapy naive patients. In univariable Cox regression models, chemotherapy exposure was associated with a hazard ratio (HR) of 0.58 (p = 0.007).In multivariable Cox regression models adjusted for case mix, chemotherapy exposure was associated with a HR of 0.60 (p = 0.016).CONCLUSIONS: To the best of our knowledge, this is the first report of chemotherapy effect on OS in mSBC patients. OS is extremely poor. Nonetheless, it is improved in a statistically significant and clinically meaningful fashion, when chemotherapy is administered.

AB - INTRODUCTION: The role of chemotherapy in metastatic sarcomatoid bladder cancer (mSBC) is unknown. The current work aimed to test the effect of chemotherapy on overall survival (OS) in mSBC patients.MATERIAL AND METHODS: Using the Surveillance, Epidemiology and End Results database (2001-2018), we identified 110 mSBC patients of all T and N stages (TanyNanyM1). Kaplan-Meier plots and Cox regression models were used. Covariates consisted of type of surgical treatment (no treatment vs radical cystectomy vs other), and patient age. The endpoint of interest was OS.RESULTS: In 110 mSBC patients, 46 (41.8%) were exposed to chemotherapy vs 64 (58.2%) who were chemotherapy naive. Chemotherapy exposed patients were younger (median age 66 vs 70, p = 0.005). Median OS was 8 months in chemotherapy exposed vs 2 months in chemotherapy naive patients. In univariable Cox regression models, chemotherapy exposure was associated with a hazard ratio (HR) of 0.58 (p = 0.007).In multivariable Cox regression models adjusted for case mix, chemotherapy exposure was associated with a HR of 0.60 (p = 0.016).CONCLUSIONS: To the best of our knowledge, this is the first report of chemotherapy effect on OS in mSBC patients. OS is extremely poor. Nonetheless, it is improved in a statistically significant and clinically meaningful fashion, when chemotherapy is administered.

U2 - 10.5173/ceju.2022.142

DO - 10.5173/ceju.2022.142

M3 - SCORING: Journal article

C2 - 36794025

VL - 75

SP - 352

EP - 356

JO - CENT EUR J UROL

JF - CENT EUR J UROL

SN - 2080-4806

IS - 4

ER -